Mark Panzenbeck
About Mark Panzenbeck
Mark Panzenbeck is a Senior Scientist in Discovery Immunology at Bristol Myers Squibb, with over 15 years of experience in inflammatory and autoimmune disease models.
Company
Mark Panzenbeck is currently working at Bristol Myers Squibb as a Senior Scientist in Discovery Immunology. Located in Cambridge, Massachusetts, United States, this position involves significant contributions to the field of immunology. Bristol Myers Squibb is known for its commitment to science and innovation in the healthcare industry. Mark's role likely includes collaboration with other scientists and teams working on breakthrough therapies for various conditions.
Title
Holding the title of Senior Scientist, Discovery Immunology, Mark Panzenbeck specializes in pre-clinical in vivo pharmacology. This senior role underscores his extensive experience and expertise in constructing experimental designs and plans to support drug discovery objectives. His work is focused on advancing scientific research in the field of immunology at Bristol Myers Squibb.
Education and Expertise
Mark Panzenbeck studied Biology at Western Connecticut State University, earning his Bachelor's degree from 2000 to 2004. With over 15 years of experience in inflammatory and autoimmune disease models, he has honed his skills in pre-clinical in vivo pharmacology. His expertise includes designing and executing experiments, as well as analyzing results to advance scientific research and development.
Background
Mark Panzenbeck has an extensive background in the pharmaceutical industry, starting his career at Boehringer Ingelheim, where he held various positions from Scientist I to Scientist IV over a period of 13 years. He then worked at Celsius Therapeutics as Scientist I and II in In Vivo Pharmacology from 2021 to 2023. His progression in these roles showcases his growth and the accumulation of significant experience in pharmacology and drug discovery.
Achievements
Throughout his career, Mark Panzenbeck has been involved in scientific research aimed at advancing drug discovery and development. His work in Discovery Immunology at Bristol Myers Squibb and previous positions at Celsius Therapeutics and Boehringer Ingelheim highlights his contribution to the field of immunology. Mark's research efforts likely include collaborations with academic institutions and using advanced data analytics tools, aiming to translate laboratory findings to patient care and potentially contributing to health equity through research initiatives.